Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen M Hattersley

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood Advances|May 15, 2023
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5Derek B Oien, Samanta Sharma, Maureen M Hattersley, et al.
Oncogene|April 12, 2018
BRD4 facilitates replication stress-induced DNA damage responseJingwen Zhang, Austin M Dulak, Maureen M Hattersley, et al.
Bioorganic & Medicinal Chemistry|December 22, 2019
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)Bin Yang, Alexander W Hird, Michael S Bodnarchuk, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2008
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancerDavid A Scott, Brian M Aquila, Geraldine A Bebernitz, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2008
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profileDavid A Scott, Kirsten J Bell, Cheryl T Campbell, et al.
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
Journal of Hematology & Oncology|November 7, 2021
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA statusFrancesca Bizzaro, Ilaria Fuso Nerini, Molly A Taylor, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood Advances|May 15, 2023
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5Derek B Oien, Samanta Sharma, Maureen M Hattersley, et al.
Oncogene|April 12, 2018
BRD4 facilitates replication stress-induced DNA damage responseJingwen Zhang, Austin M Dulak, Maureen M Hattersley, et al.
Bioorganic & Medicinal Chemistry|December 22, 2019
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)Bin Yang, Alexander W Hird, Michael S Bodnarchuk, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2008
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancerDavid A Scott, Brian M Aquila, Geraldine A Bebernitz, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2008
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profileDavid A Scott, Kirsten J Bell, Cheryl T Campbell, et al.
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
Journal of Hematology & Oncology|November 7, 2021
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA statusFrancesca Bizzaro, Ilaria Fuso Nerini, Molly A Taylor, et al.
Pageof 2